

Gaia Giannone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8134241/publications.pdf>

Version: 2024-02-01

12
papers

443
citations

1163117

8
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

779
citing authors

#	ARTICLE	IF	CITATIONS
1	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1205-1207.	2.5	5
2	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). <i>Gynecologic Oncology</i> , 2021, 161, 755-761.	1.4	9
3	The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality. <i>Frontiers in Oncology</i> , 2021, 11, 689829.	2.8	9
4	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. <i>Cells</i> , 2021, 10, 3408.	4.1	4
5	Olaparib as maintenance therapy in patients with BRCA 1&2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020, 156, 38-44.	1.4	62
6	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. <i>Journal of Ovarian Research</i> , 2020, 13, 53.	3.0	6
7	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020, 10, 146.	2.6	56
8	Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2353.	4.1	24
9	TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 17.	3.0	20
10	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1820.	3.7	57
11	PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 392-410.	1.6	102
12	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017, 8, 90532-90544.	1.8	89